NUVB vs DCOM Comparison

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Dime Community Bancshares Inc operates as a holding company. The company gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, and mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.